Nivolumab Wins First-Line Indication in Metastatic UC

The FDA approved nivolumab alongside cisplatin and gemcitabine in the frontline for adults with unresectable or metastatic disease.
Medscape Medical News

source https://www.medscape.com/viewarticle/nivolumab-wins-first-line-indication-metastatic-urothelial-2024a10004g4?src=rss

Comments

Popular posts from this blog

RA and RA-ILD Linked to Higher Lung Cancer Risk

New AAFP practice guideline sets blood pressure targets for adults with hypertension

Heart Failure Care Outside of ICU Can Lower Cost